Alpha 2.0
Login Register
» Authors » E I Andersson

E I Andersson

Explore the profile of E I Andersson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 276
Followers 0
Related Specialties
Oncology
Hematology
Biology
Top 10 Co-Authors
S Mustjoki
O Kallioniemi
K Porkka
S Eldfors
T Pemovska
S Lagstrom
T H Brummendorf
B Yadav
P Ellonen
M Herling
Published In
Leukemia
Blood Cancer J
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Putzer S, von Jan J, et al.
Nat Commun . 2018 Feb; 9(1):697. PMID: 29449575
T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences...
2.
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
Andersson E, Putzer S, Yadav B, Dufva O, Khan S, He L, et al.
Leukemia . 2017 Aug; 32(3):774-787. PMID: 28804127
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival...
3.
Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis
Savola P, Kelkka T, Rajala H, Kuuliala A, Kuuliala K, Eldfors S, et al.
Nat Commun . 2017 Jun; 8:15869. PMID: 28635960
Somatic mutations contribute to tumorigenesis. Although these mutations occur in all proliferating cells, their accumulation under non-malignant conditions, such as in autoimmune disorders, has not been investigated. Here, we show...
4.
Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach
Coppe A, Andersson E, Binatti A, Gasparini V, Clemente M, Herling M, et al.
Leukemia . 2017 Feb; 31(5):1243-1246. PMID: 28167832
No abstract available.
5.
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
Pietarinen P, Pemovska T, Kontro M, Yadav B, Mpindi J, Andersson E, et al.
Blood Cancer J . 2015 May; 5:e309. PMID: 25933373
Chronic myeloid leukemia in blast crisis (CML BC) remains a challenging disease to treat despite the introduction and advances in tyrosine kinase inhibitor (TKI) therapy. In this study we set...
6.
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
Kontro M, Kuusanmaki H, Eldfors S, Burmeister T, Andersson E, Bruserud O, et al.
Leukemia . 2014 Feb; 28(8):1738-42. PMID: 24573384
No abstract available.
7.
Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
Andersson E, Rajala H, Eldfors S, Ellonen P, Olson T, Jerez A, et al.
Blood Cancer J . 2013 Dec; 3:e168. PMID: 24317090
T-cell large granular lymphocytic (T-LGL) leukemia is a clonal disease characterized by the expansion of mature CD3+CD8+ cytotoxic T cells. It is often associated with autoimmune disorders and immune-mediated cytopenias....